Research programme: kallikrein inhibitors - IBEX
Latest Information Update: 14 Apr 2011
At a glance
- Originator IBEX Technologies
- Mechanism of Action Kallikrein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Ovarian cancer; Prostate cancer
Most Recent Events
- 12 Jan 2005 Preclinical trials in Prostate cancer in Canada (unspecified route)
- 12 Jan 2005 Preclinical trials in Ovarian cancer in Canada (unspecified route)